enGene Holdings Inc.

NASDAQ:ENGN

Biotechnology

Healthcare
$1.85 -1.15%

-$0.02 today

Market cap
$123.98M
Beta
-0.29
P/E (TTM)
-1.8
EPS (TTM)
-$0.95
52W Low $1.40High $12.25

Volume 2.81M

Average 1.58M

ENGN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

enGene Holdings Inc.NASDAQ: ENGN

Stock-Based Compensation · Q2 FY2026 · quarter ended Apr 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q2 FY2026 stock-based compensation of $4.15M rose 56.4% year over year, behind the +60.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 47.9% from the prior quarter. Over 3 fiscal years it compounded at +336.5% a year.

Context

  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +56.4% toward the trailing-twelve-month pace of +60.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterApr 2026
$4.15M+47.9% QoQ
Last fiscal yearOct 2025
$9.65M+81.2% YoY
LTMApr 2026
$12.14M+60.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+56.4%——
1 year+81.2%——
3-year CAGR+336.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
9.65M USD
Year-over-year change
+81.2%
4-year CAGR
+117.0%

Stock-Based Compensation vs competitors

How ENGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +60.2% is the highest of 10, against a peer median of -15.9%.
  • Over three fiscal years its annual growth of +336.5% compares with a peer median of +2.3%.
ENGN Competitors
Stock-Based Compensation for ENGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$15.5M USD-21.9%-3.9%—
ALTAltimmune, Inc.LTM Mar 2026$15.44M USD+4.6%+25.7%42886.1%
SLNSilence Therapeutics plcLTM Mar 2026$14.34M USD—-14.0%1556.3%
ENGNenGene Holdings Inc.LTM Apr 2026$12.14M USD+60.2%+336.5%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$7.15M USD-15.9%+1.9%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$7.02M USD-5.4%+66.3%—
DBVTDBV Technologies S.A.LTM Mar 2026$5.99M USD+37.2%+2.3%—
KRROKorro Bio, Inc.LTM Mar 2026$4.8M USD-10.4%+88.7%125.0%
AMRNAmarin Corporation plcLTM Mar 2026$3.95M USD-191.3%—1.8%
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
CLLSCellectis S.A.LTM Mar 2026$1.28M USD-60.6%—1.9%
Peer median (excluding ENGN) —-15.9%+2.3%100.0%

Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Net Income(23.44M)(24.46M)(99.92M)(55.14M)(117.3M)
Depreciation & Amortization272K238K175K323K509K
Deferred Income Tax00000
Stock-Based Compensation435K116K3.45M5.32M9.65M
Change in Working Capital(1.04M)2.17M(517K)95K9.74M
Accounts Receivables295K143K(1.01M)2.01M(595K)
Inventory00000
Accounts Payables110K(197K)373K474K4.94M
Other Working Capital(1.44M)2.23M117K(2.39M)5.39M
Other Non-Cash Items7.79M4.34M72.07M1.12M(1.83M)
Operating Cash Flow(15.98M)(17.59M)(24.74M)(48.28M)(99.24M)
Capital Expenditures(248K)(153K)(318K)(925K)(1.49M)
Acquisitions (Net)00000
Purchases of Investments000(125.03M)(160.84M)
Sales of Investments0000137.19M
Other Investing Activities1K0000
Investing Cash Flow(247K)(153K)(318K)(125.95M)(25.14M)
Debt Repayment7.07M28.39M33.27M13.06M(699K)
Common Stock Issued14K12K56.89M260.15M2.22M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(144K)(423K)(4.01M)(7.49M)0
Financing Cash Flow22.53M27.97M86.15M265.72M1.52M
Effect of Forex Changes98K(805K)1K1K1K
Net Change in Cash6.39M9.42M61.09M91.48M(122.85M)
Free Cash Flow(16.23M)(17.75M)(25.06M)(49.21M)(100.72M)

enGene Holdings Inc.

NASDAQ:ENGN

Intrinsic Alpha fair value

Locked

Current Price

$1.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.